Open AccessShunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
Author(s) -
Kuwahara Ai,
Sasaki Ryu,
Fukushima Masanori,
Haraguchi Masafumi,
Miuma Satoshi,
Miyaaki Hisamitsu,
Nakao Kazuhiko
Publication year - 2020
Publication title -
jgh open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 8
ISSN - 2397-9070
DOI - 10.1002/jgh3.12351
Subject(s) - medicine , sorafenib , hyperammonemia , hepatic encephalopathy , portosystemic shunt , encephalopathy , cirrhosis , lenvatinib , hepatocellular carcinoma , gastroenterology , surgery , portal hypertension
Shunt occlusion prior to lenvatinib administration prevented hyperammonemia and hepatic encephalopathy. Shunt occlusion may be an effective treatment option to administer molecular target agents in patients with portosystemic shunts.